Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1803]
News [2707]
Articles [198]
Editorials [1]
Conferences [135]
elearning [13]
The 2022 OncoAlert Colloquium Day 5: GI Oncology
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 5: GI Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 3: Lung Cancer
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 3: Lung Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 2: GU Oncology
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 2: GU Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 1: Breast Cancer
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 1: Breast Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
30 Jan 2023
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy...
Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer ( Dr Thomas George - University of Florida Health Cancer Center, Gainesville, USA )
26 Jan 2023
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and...
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
25 Jan 2023
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2023
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )
13 Jan 2023
ASH 2022: Multiple myeloma roundup
Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA
ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )
22 Dec 2022
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...
Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA
Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )
21 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation